Eiger BioPharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update

PALO ALTO, Calif.May 7, 2020 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for first quarter 2020 and provided a business update. Continue reading

Bausch Health Initiates VIRAZOLE® (Ribavirin for Inhalation Solution, USP) Clinical Study in Patients with COVID-19

Bausch Health Is Working with Multiple Health Authorities to Make VIRAZOLE Available as a Potential Treatment for COVID-19

LAVAL, QuebecApril 13, 2020 /PRNewswire/ — Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”) today announced it has initiated a clinical trial program in Canada evaluating an investigational use of VIRAZOLE® (Ribavirin for Inhalation Solution, USP) in combination with standard of care therapy to treat hospitalized adult patients with respiratory distress due to COVID-19. Because ribavirin is a synthetic nucleoside that works to stop viral replication, VIRAZOLE may be effective in reducing the severity of COVID-19 infection. Continue reading

U.S. FDA Grants CytoSorb® Emergency Use Authorization for Use in Patients with COVID-19 Infection

MONMOUTH JUNCTION, N.J.April 13, 2020 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a  critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, announced the United States Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) of CytoSorb® for use in patients with COVID-19 infection. Continue reading